Author: Fiona Craig

Canadian Defence Department Selects Auxilium Suite

Pennant International (LSE:PEN) has secured a multiyear Integrated Product Support services contract through its Canadian subsidiary to provide and optimise its Auxilium software suite for maritime programmes within Canada’s Department of National Defence (DND).

The agreement strengthens Pennant’s long-standing relationship with the DND and further expands the deployment of its Auxilium platform, which combines the GenS, Analyzer and R4i applications to support the management of complex equipment data and regulatory compliance requirements.

Contract Could Deliver Up to C$35 Million in Revenue

The framework agreement has an initial term of five years and includes extension options that could take the total duration to 11 years.

Based on historic usage levels, Pennant estimates the contract will generate approximately C$15 million during the initial period and could be worth as much as C$35 million over its full lifespan. The award provides additional visibility over future revenues and supports the continued expansion of the group’s software and services operations.

Software Strategy Focused on Recurring Revenue Growth

Auxilium forms a central part of Pennant’s strategy to increase recurring revenues through software solutions used in highly regulated industries.

The platform helps customers manage technical documentation, maintenance information and product support requirements while ensuring compliance with industry standards. Demand for such solutions is being driven by rising defence spending and the increasing complexity of modern military and industrial platforms.

With operations across the UK, North America and Asia-Pacific, Pennant continues to target opportunities in sectors where long-term support, data management and compliance are critical.

Financial Challenges Continue to Weigh on Outlook

Despite the positive contract win, the company’s outlook remains affected by recent financial performance. Revenue declined during 2025, operating losses re-emerged and pressure on shareholder equity persisted.

Technical indicators also remain weak, with the share price trading below key moving averages and momentum measures such as the RSI signalling limited investor enthusiasm. Valuation metrics offer little support, as the company remains loss-making and does not currently provide a dividend yield.

More About Pennant International

Pennant International Group is a technology-focused provider of integrated support software, technical services and training solutions for organisations operating complex assets. The company serves customers across the aerospace, defence and rail sectors, as well as other safety-critical industries including shipping, nuclear energy and space. Pennant is increasingly focused on expanding higher-margin, recurring software and support revenues as part of its long-term growth strategy.

Term Loan Reaches Strongest Level Since 2021

THG PLC (LSE:THG) has announced that its €445 million Term Loan B, issued in March 2025, has traded above par value for the first time and reached its highest level since November 2021.

The milestone follows a succession of positive trading updates throughout 2025 and 2026 and marks the strongest performance recorded by any of the group’s term loan facilities in nearly five years.

Secondary Market Performance Outpaces Industry Benchmark

Since the beginning of 2026, the loan has appreciated by approximately 500 basis points, resulting in a reduction in yield of around 1.3%.

Over the same period, the facility has outperformed the European Leveraged Loan Index by roughly 400 basis points, highlighting growing investor appetite for THG’s debt and improving sentiment towards the company’s credit profile.

The performance reflects increasing confidence among lenders and institutional investors in the group’s financial outlook and strategic direction.

Stronger Credit Perception Could Improve Financing Options

The move above par value is a notable indicator of market confidence and may enhance THG’s future access to capital.

A stronger trading performance in the debt market can improve funding flexibility, potentially reducing borrowing costs and strengthening the company’s position should it seek refinancing or additional financing opportunities in the future.

Management views the performance as evidence of the positive reception received from investors following recent operational and trading progress.

Financial Recovery Continues Despite Ongoing Challenges

While market sentiment towards the company’s debt has improved, THG’s broader financial outlook remains constrained by ongoing profitability and cash flow challenges.

Although earnings improved during 2025, the group continues to report negative operating profitability, while both operating cash flow and free cash flow remain negative. Leverage levels also continue to be relatively elevated.

Technical indicators provide some support, with momentum measures remaining positive. Valuation metrics appear broadly moderate based on earnings multiples, although the absence of a dividend limits the stock’s appeal for income-focused investors.

More About THG

THG PLC is a global e-commerce and consumer brands group headquartered in Manchester. The company operates through its THG Beauty and THG Nutrition divisions, serving customers across international markets.

THG Beauty manages major online retail platforms including Lookfantastic, Dermstore and Cult Beauty, offering products from more than 1,000 third-party brands alongside its own portfolio. THG Nutrition is led by Myprotein, one of the world’s largest online sports nutrition brands, and provides a wide range of health, wellness and performance products through both direct-to-consumer and wholesale channels.

Regulatory Milestone Achieved in Rare Disease Programme

GSK (LSE:GSK) has been granted Orphan Drug Designation by both U.S. and European regulatory authorities for momelotinib as a potential treatment for VEXAS syndrome, a rare and life-threatening clonal myeloid disorder that currently has no approved therapies.

The condition is associated with significant morbidity and a high mortality rate within five years of diagnosis, creating a substantial unmet medical need for affected patients.

Momelotinib Could Address Multiple Disease Pathways

Momelotinib is already approved in several major markets for the treatment of specific myelofibrosis indications and works by targeting the JAK1, JAK2 and ACVR1 pathways.

The drug’s mechanism of action may provide benefits for patients with VEXAS syndrome by helping to manage inflammatory symptoms while also addressing anaemia, a common and debilitating feature of the disease. This positions the therapy as a potential treatment option for patients suffering from severe haemato-inflammatory disorders.

Designations Support Development and Regulatory Progress

The orphan designations are expected to facilitate the development and regulatory pathway for momelotinib as GSK continues to advance its Phase II/III ATLAS clinical trial.

The study is evaluating the safety and efficacy of the treatment in patients with VEXAS syndrome and will form a key part of the company’s future global regulatory submissions.

If successful, the programme could expand momelotinib’s commercial opportunity beyond myelofibrosis and establish a presence in a new rare disease indication, further strengthening GSK’s position within the haematology market.

Financial Strength Balances Development Opportunity

GSK’s outlook continues to be supported by strong underlying operating performance, including healthy profit margins and improving earnings trends. The company also benefits from a relatively attractive valuation, supported by a low price-to-earnings ratio and a dividend yield of approximately 3.47%.

These strengths are partially offset by weaker technical indicators, with the shares trading below key moving averages and showing a negative MACD reading. Investors also continue to monitor financial risks associated with leverage levels and fluctuations in free cash flow generation.

More About GSK

GSK is a global biopharmaceutical company focused on the research, development and commercialisation of innovative medicines and vaccines. The company operates across a broad range of therapeutic areas and is increasingly expanding its presence in haematology and inflammatory diseases while continuing to build on its established portfolio of specialty medicines and vaccines.

Production Growth Driven by Strong Harvest and Improved Extraction Rates

M.P. Evans (LSE:MPE) reported solid operational progress during the five months to 31 May 2026, with fresh fruit bunch production increasing 10% to 575,100 tonnes and crude palm oil (CPO) output rising 8% to 157,600 tonnes.

The improvement was supported by stronger extraction rates and the company’s continued focus on expanding production from its own-managed plantations, which typically deliver higher-quality yields than externally sourced crop.

Sustainability also remained a key focus, with approximately 82% of the group’s CPO production now certified as sustainable.

Pricing Remains Supportive as Costs Stay Under Control

The company said market conditions remained favourable, with both crude palm oil and palm kernel prices continuing to trade at healthy levels.

Despite broader inflationary pressures affecting agricultural inputs globally, M.P. Evans maintained broadly stable unit production costs, supporting profitability and operational efficiency across its plantation portfolio.

Management also noted that proposed changes to Indonesian export regulations are not expected to have a material impact on the business, as the group sells its palm oil into the domestic market rather than exporting CPO directly. To date, no significant effect on pricing has been observed.

Capital Returns Strengthened Through Buybacks and Dividend Growth

M.P. Evans highlighted continued progress at its recently acquired estates in East Kalimantan, where yields are improving as integration efforts advance.

Reflecting confidence in the business and its outlook, the company has resumed its share buyback programme with an initial £2.0 million allocation. It also plans to seek broader buyback authority from shareholders at its upcoming annual general meeting.

In addition, the board has proposed a record total dividend of 60p per share for 2025, reinforcing its commitment to a progressive capital-return strategy.

Strong Fundamentals Continue to Support Outlook

The group’s outlook remains underpinned by robust financial performance, characterised by strong profitability, solid cash generation and a debt-free balance sheet.

Valuation metrics also remain attractive, supported by a low price-to-earnings ratio and a healthy dividend yield. While technical indicators continue to point to a positive longer-term trend, elevated RSI and stochastic readings suggest momentum may be stretched in the near term, potentially limiting short-term upside.

More About M.P. Evans

M.P. Evans Group PLC is a UK-listed producer of sustainable palm oil with plantation and milling operations across Indonesia. The company focuses on producing higher-quality crude palm oil and palm kernels from its own-managed estates, supplying domestic Indonesian refiners rather than exporting directly. Through its emphasis on operational efficiency, sustainability and RSPO-certified production, the group has established itself as a significant participant in Indonesia’s palm oil sector.

Italian Solar Portfolio Positioned to Benefit from State Support

Zenith Energy (LSE:ZEN) is seeking to capitalise on Italy’s newly approved €23 billion renewable energy support programme through its solar development subsidiary, WESOLAR.

The company currently controls a solar portfolio with a total capacity of 188.5 MWp and is focusing on projects below 10 MWp in strategically selected areas to streamline permitting procedures and secure grid access more efficiently. Construction of WESOLAR’s first 7 MWp project cluster in the Puglia region is scheduled to begin in July 2026.

Long-Term Revenue Support Could Enhance Project Economics

The Italian initiative, which has received backing from the European Union, is designed to accelerate the deployment of renewable electricity generation across the country. The scheme will provide successful projects with 20-year two-way Contracts for Difference (CfDs), offering greater revenue certainty and reducing exposure to power price volatility.

The programme is expected to support the development of approximately 37.15 GW of new renewable energy capacity, including solar installations. Zenith believes its WESOLAR projects could qualify for the scheme, potentially improving project economics and strengthening the attractiveness of its development pipeline.

Financing and Asset Values Could Receive a Boost

Should WESOLAR secure access to the programme, Zenith expects the enhanced revenue visibility to improve financing opportunities for its projects and support higher asset valuations.

The company believes this could further strengthen its build-and-sell business model, increasing the appeal of its renewable assets to lenders, infrastructure investors and institutional buyers as Italy continues to expand its renewable energy capacity.

Financial and Technical Challenges Remain

Despite the growth opportunity presented by the Italian renewables market, Zenith’s outlook continues to be weighed down by financial pressures. The company has reported recurring negative operating and free cash flow, returned to significant losses in 2026 and has seen debt levels increase.

Technical indicators also remain weak, with a negative MACD reading and the share price trading below key moving averages, suggesting a bearish trend. Valuation metrics remain constrained by the company’s loss-making position, resulting in a negative price-to-earnings ratio and no dividend support.

More About Zenith Energy

Zenith Energy Ltd. is an independent energy company with producing, exploration and development assets across North Africa, the United States and Europe. Listed in London, Oslo and on Sweden’s Spotlight market, the company focuses on acquiring and developing proven energy assets capable of generating cash flow while pursuing low-risk exploration opportunities in established producing regions.

U.S. Patent Secures Protection for CIZ1B Testing Technology

Cizzle Biotechnology (LSE:CIZ) has been granted a significant U.S. patent covering its proprietary methods for detecting and measuring the CIZ1B lung cancer biomarker. The award extends the company’s intellectual property protection in a key market, complementing existing patent coverage across Europe and Canada.

The patent is expected to support the commercial activities of Cizzle Bio Inc, the company’s North American licensing partner, which is preparing to introduce the two-step ELISA-based lung cancer test across the United States and Caribbean region.

Expanded IP Coverage Supports Commercialisation Strategy

The latest patent strengthens Cizzle’s broader strategy of licensing its early-stage lung cancer diagnostic technology worldwide. Management believes the enhanced intellectual property position will help create additional opportunities for licensing agreements and future royalty streams.

Protection across North America and Europe is also expected to support discussions with clinical laboratories, healthcare providers and NHS-associated organisations as the company advances the commercial rollout of its blood-based cancer detection test.

Focus on Earlier Cancer Detection

Cizzle’s technology is designed to assist in the early identification of lung cancer through a simple blood test that measures the CIZ1B biomarker. The company aims to align the deployment of the test with wider healthcare initiatives focused on improving early diagnosis rates and patient outcomes.

A stronger patent portfolio is expected to play an important role in supporting adoption and partnership opportunities as the technology moves into additional markets.

Financial Challenges Continue Despite Technical Momentum

The company’s outlook remains constrained by its financial profile, which includes a lack of revenue generation, ongoing losses and continued cash consumption. Negative profitability and the absence of dividend support also weigh on valuation metrics.

However, technical indicators have remained favourable, reflecting a strong upward trend in the share price. Investors should note that momentum measures currently suggest overbought conditions, which may increase near-term volatility.

More About Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings PLC is a UK-based life sciences company focused on the development of diagnostic technologies for the early detection of cancer, with a particular emphasis on lung cancer. Its lead product is a non-invasive blood test designed to detect the CIZ1B biomarker. The company operates a global licensing model that includes royalty-based agreements and collaborations with healthcare providers and cancer treatment centres, leveraging its London Stock Exchange listing to support commercial growth.

Fund Releases Latest Monthly Investor Report

TwentyFour Select Monthly Income Fund (LSE:SMIF) has published its monthly factsheet and portfolio commentary for the period ending 31 May 2026, giving investors an updated overview of the fund’s performance, strategy and market positioning.

The materials have been made available through the company’s website as part of its regular reporting programme, reflecting the fund’s commitment to providing timely and transparent information to shareholders and market participants.

Ongoing Reporting Supports Investor Engagement

The publication of detailed monthly updates remains a key component of the fund’s communication strategy, helping investors track developments within the portfolio and assess the fund’s positioning across credit markets.

By maintaining a consistent reporting schedule, the company aims to support informed investment decisions among both existing shareholders and prospective investors, particularly within the income-focused segment of the fixed-income market.

Focus on Specialist Credit Opportunities

The fund continues to position itself as a specialist investor in less liquid debt instruments, where active management and market expertise can help identify opportunities that may be less accessible to broader fixed-income strategies.

Regular portfolio disclosures also provide greater visibility into the fund’s operations and investment approach, helping reinforce confidence in its long-term income-generating strategy.

More About TwentyFour Select Monthly Income Fund

TwentyFour Select Monthly Income Fund Limited is a closed-ended investment company listed in London that seeks to generate attractive income returns through investments in less liquid areas of the debt market. The fund primarily targets professional and institutional investors and invests across a diversified range of credit assets, leveraging specialist expertise to identify opportunities within fixed-income markets that may offer enhanced yields.

Annual Results Highlight Portfolio Resilience

Picton Property Income (LSE:PCTN) has reported preliminary annual results showing net assets of £522 million, EPRA NTA of 102p per share and a total return of 6.1%, while total shareholder return came in at 12.6%.

The company’s performance was supported by 5% rental growth, ongoing outperformance of the MSCI UK Quarterly Property Index over a 13-year period and a disciplined approach to capital allocation. During the year, Picton returned capital to investors through £17.3 million of share buybacks while continuing to increase its exposure to industrial assets.

Portfolio Growth Offsets Occupancy Decline

The property portfolio delivered a 1.7% like-for-like valuation increase alongside estimated rental value growth of 4.8%. However, occupancy fell to 84% following two significant industrial lease events.

Despite this, the group maintained a conservative financial position, supported by a loan-to-value ratio of 24% and a fully fixed-rate debt structure. The company also continued to make progress against its sustainability objectives during the year.

Strategic Review Attracts Potential Bidders

Picton is currently engaged in a formal sale process after receiving a non-binding all-share proposal from LondonMetric Property and Schroder Real Estate Investment Trust.

The approach has the potential to alter the company’s ownership structure and could create additional value opportunities for shareholders as the review process progresses.

Valuation Remains Attractive Despite Mixed Financial Signals

The company’s outlook continues to benefit from favourable valuation metrics, including a low price-to-earnings ratio and an elevated dividend yield, both of which may indicate potential undervaluation.

While profitability remains strong, revenue and cash flow trends have been less consistent. Technical indicators remain broadly neutral, offering little indication of a clear near-term market direction.

More About Picton Property Income

Picton Property Income is a UK-focused real estate investment trust with a commercial property portfolio valued at approximately £701 million. Listed on the London Stock Exchange, the company owns 46 assets occupied by around 300 tenants across the UK. Its portfolio is predominantly weighted towards industrial properties, and the group aims to deliver upper-quartile performance against the MSCI UK Quarterly Property Index while targeting net zero carbon emissions by 2045.

Management Share Award Supports Long-Term Alignment

EasyJet (LSE:EZJ) has awarded 27,071 restricted shares to PDMR Garry Wilson under its Restricted Share Plan. The award has been granted as a nil-cost option and is expected to vest in December 2028, subject to performance underpins being met. The grant reflects the airline’s ongoing commitment to using share-based remuneration to align senior executives with long-term shareholder value creation and business performance objectives.

Employee Share Scheme Expands Staff Participation

In a separate transaction, the trustee of EasyJet’s Share Incentive Plan acquired 31 partnership shares for each of the company’s PDMRs Robert Birge, Kenton Jarvis, David Morgan and Garry Wilson at a price of £4.79 per share. The purchases were financed through monthly salary deductions.

The HMRC-approved scheme enables employees to invest up to £150 per month in EasyJet shares, supporting the company’s objective of increasing employee ownership and strengthening the connection between staff rewards and the airline’s share price performance.

Outlook Remains Supported by Profitability and Balance Sheet Strength

EasyJet’s investment case continues to be underpinned by improving profitability and a robust balance sheet. The company also benefits from an attractive valuation, supported by a relatively low price-to-earnings ratio and dividend yield.

While technical indicators remain favourable, they suggest the shares may be approaching overbought territory. Recent management commentary has been constructive regarding liquidity and medium-term growth ambitions, although near-term pressures from operating costs and demand trends remain areas of focus.

More About EasyJet

EasyJet plc is a UK-based low-cost airline serving short-haul routes across Europe and selected international markets. The carrier targets both leisure and business travellers, competing within the budget airline sector through efficient fleet utilisation, ancillary revenue generation and a large-scale operating network across the European aviation market.